106 related articles for article (PubMed ID: 16316856)
1. Reversible Z-E isomerism and pharmaceutical implications for SU5416.
Sistla A; Shenoy N
Drug Dev Ind Pharm; 2005 Dec; 31(10):1001-7. PubMed ID: 16316856
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS.
Zhao Y; Sukbuntherng J
J Pharm Biomed Anal; 2005 Jul; 38(3):479-86. PubMed ID: 15925249
[TBL] [Abstract][Full Text] [Related]
3. Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine.
Posocco B; Buzzo M; Giodini L; Crotti S; D'Aronco S; Traldi P; Agostini M; Marangon E; Toffoli G
J Pharm Biomed Anal; 2018 Oct; 160():360-367. PubMed ID: 30119000
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.
Zhao Y; Sukbuntherng J; Antonian L
J Pharm Biomed Anal; 2004 May; 35(3):513-22. PubMed ID: 15137976
[TBL] [Abstract][Full Text] [Related]
5. High-performance liquid chromatographic method for determination of reversible isomers of SU5416.
Sistla A; Yang WL; Shenoy N
J Chromatogr A; 2006 Mar; 1110(1-2):73-80. PubMed ID: 16472814
[TBL] [Abstract][Full Text] [Related]
6. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.
Zhao Y; Yang CY; Haznedar J; Antonian L
J Pharm Biomed Anal; 2001 Jul; 25(5-6):821-32. PubMed ID: 11377065
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib loaded chitosan nanoparticles formulation and its evaluation.
Joseph JJ; Sangeetha D; Gomathi T
Int J Biol Macromol; 2016 Jan; 82():952-8. PubMed ID: 26522243
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
[TBL] [Abstract][Full Text] [Related]
10. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
[TBL] [Abstract][Full Text] [Related]
11. Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Tohnya TM; Kim S; Fine HA; Dunn L; Figg WD; Sparreboom A
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(1):135-40. PubMed ID: 15113549
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
13. Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent).
Sistla A; Kertelj A; Shenoy N
PDA J Pharm Sci Technol; 2008; 62(3):200-10. PubMed ID: 18661869
[TBL] [Abstract][Full Text] [Related]
14. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.
Pandit B; Sun Y; Chen P; Sackett DL; Hu Z; Rich W; Li C; Lewis A; Schaefer K; Li PK
Bioorg Med Chem; 2006 Oct; 14(19):6492-501. PubMed ID: 16860559
[TBL] [Abstract][Full Text] [Related]
16. The influence of light sources on sunitinib measurements with photoisomerization.
Matsunaga N; Kitahara T; Yamada M; Sato K; Kodama Y; Sasaki H
Biomed Chromatogr; 2019 Feb; 33(2):e4407. PubMed ID: 30315654
[TBL] [Abstract][Full Text] [Related]
17. Actinometric and Φ-order photodegradation properties of anti-cancer Sunitinib.
Maafi M; Lee LY
J Pharm Biomed Anal; 2015 Jun; 110():34-41. PubMed ID: 25796061
[TBL] [Abstract][Full Text] [Related]
18. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
19. Effects of light intensity, n-alcohols, water-soluble colorants, and solution viscosity on photoisomerization of sorivudine.
Desai D; Li D; Janjikhel R; Lang B; Jain N
Pharm Dev Technol; 2001; 6(1):99-106. PubMed ID: 11247280
[TBL] [Abstract][Full Text] [Related]
20. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
